WACKER has developed a patented manufacturing process that should lower production cost by creating a more efficient and scalable synthesis for Amdoxovir^®. Under the terms of the agreement, RFS Pharma will have exclusive rights to the new and improved process for the synthesis of Amdoxovir^®. Amdoxovir^® belongs to the class of nucleoside analogue reverse transcriptase inhibitors (NRTIs) and has been safely administered to over 200 adults in seven Phase 1 and 2 clinical studies.

RFS Pharma, LLC, was founded in September 2004 and is located in a 26,500 sq. ft. state-of-the-art research facility in Tucker, Georgia (USA). RFS Pharma is a privately owned biotech company committed to the discovery and development of antiviral agents and other human therapeutics. The company capitalizes on its expertise in nucleoside chemistry to develop drugs to combat infections caused by drug-resistant HIV and hepatitis viruses. For further information about RFS Pharma, please refer to www.rfspharma.com.

The WACKER Group (www.wacker.com) is a globally active chemical company headquartered in Munich, Germany. With a wide range of state-of-the-art specialty products, WACKER is a leader in numerous industrial sectors. Its products are required in countless high-growth end-user sectors such as photovoltaics, electronics, pharmaceuticals and household/personal care products. In 2007, the WACKER Group posted sales of €3.78 billion, of which approx. 80 percent is generated outside Germany. WACKER has about 15,000 employees at 27 production sites in Europe, the Americas and Asia and at some 100 sales offices worldwide.